Showing posts with label pregabalin. Show all posts
Showing posts with label pregabalin. Show all posts

Wednesday, May 28, 2008

What to do about essential tremor


I recently gave a presentation at UCLA, after which a very nice woman asked me if I knew anything about diet and essential tremor. I did not, and I promised to get back to her. What I learned took a little while to get through! For her benefit and the rest of you reading this, here is a short synopsis.

Essential tremor is very strongly genetic. Interestingly, at the same time I was reading research on the topic, I was reading a biography of our second President, John Adams. I learned that he, his son, and his famous cousin Samuel all experienced the affliction, as evidenced in handwriting samples available for analysis. Samuel's tremor was so bad that toward the end of his life he had to dictate all of his correspondence. There was some alcoholism in the family, to which some of this may be attributed, but even so, a genetic link seems to be apparent.

As far as dietary considerations, some of the more common considerations have been whether or not caffeine and ethanol (alcohol) consumption are correlated with tremor severity. While caffeine intake is lower in people who have tremors, tremor severity is not clearly correlated with total caffeine intake. So the reason for this association is not completely understood. Ethanol appears to have a more consistent influence on tremors.

Reduced body mass is a common problem with essential tremor, likely because of the energy spent in nonproductive muscle activity. One research group recommended that physicians pay attention to this and encourage adequate nutritional intake in persons with essential tremor. There may be an interesting conflict in this observation, in that individuals who are trying to gain weight tend to eat more protein...and red meat intake was recently associated with a greater degree of tremor severity in men (not women). This finding underlies the importance of not giving out dietary advice unless it is specifically evidence-based with regard to the problem at hand, not just general advice that might work on the average person.

My friend asked me specifically about the potential for using omega-3 fatty acids to help with tremors. To date, no research is in Pub Med regarding this possibility. However, it was only in April 2008 that the potential connection between omega-3 intake and Parkinson's disease showed up in the literature, so I would venture to guess it won't be long before this research is available.

Supporting my assumption is the fact that a correlation has been shown between a Mediterranean diet pattern and a lower incidence of essential tremor. Even though there is research suggesting that the blood components associated with essential tremor and red meat consumption don't consistently explain the origin of tremors, you have to admit, it certainly never hurts, for many reasons, to eat more fish and less red meat, more fruits and vegetables and healthy fats!

In going through my medication fact sheets, I find that three of the psychotropic medications I regularly research have been reported as being used in an off-label fashion for essential tremor. These medications are olanzapine (Zyprexa), pregabalin (Lyrica), and topiramate (Topamax). Olanzapine and pregabalin are associated with weight gain, and topiramate with weight loss. Given the fact that weight change even in the absence of medications is a problem, it would seem that minimizing the dosages of medications that might interfere with overall health would be an important consideration. Medications can also change one's appetite for certain kinds of food. My experience is that, especially with olanzapine, appetites for carbohydrates and the wrong kind of fats can intensify, which can make adherence to a Mediterranean diet challenging.

The dietary emphases I describe above, to start with the Mediterranean diet in hopes of decreasing the necessary dose of medication for tremor management, would be the most ideal combination of approaches.

I also found some interesting effective non-pharmaceutical therapies that might be worthwhile to try. Who knows, maybe they can help put all that good nutrition into muscle and nerve tissue where it's needed, and prevent unnecessary loss of important tissues. Weight training, for example, improved their steadiness and decreased the magnitude of their tremors. Behavioral relaxation training was also found to reduce tremor severity.

Quite an interesting--albeit unexpected research project! Thank you for stimulating my interest in compiling information with potential to help others.

Lundervold DA, Belwood MF, Craney JL, Poppen R. Reduction of tremor severity and disability following behavioral relaxation training. J Behav Ther Exp Psychiatry. 1999 Jun;30(2):119-35.

Paulson G. Illnesses of the brain in John Quincy Adams. J Hist Neurosci. 2004 Dec;13(4):336-44.

Louis ED, Kavanagh P, Gertrude H. John Adams' essential tremor. Mov Disord. 2005 Dec;20(12):1537-42.

Louis ED, Jurewicz EC, Applegate L, Luchsinger JA, Factor-Litvak P, Parides M.Semiquantitative study of current coffee, caffeine, and ethanol intake in essential tremor cases and controls. Mov Disord. 2004 May;19(5):499-504.

Dogu O, Sevim S, Louis ED, Kaleagasi H, Aral M. Reduced body mass index in patients with essential tremor: a population-based study in the province of Mersin, Turkey. Arch Neurol. 2004 Mar;61(3):386-9.

Louis ED, Keating GA, Bogen KT, Rios E, Pellegrino KM, Factor-Litvak P. Dietary epidemiology of essential tremor: meat consumption and meat cooking practices. Neuroepidemiology. 2008;30(3):161-6.

Scarmeas N, Louis ED. Mediterranean diet and essential tremor. A case-control study. Neuroepidemiology. 2007;29(3-4):170-7.

Louis ED, Zheng W, Applegate L, Shi L, Factor-Litvak P. Blood harmane concentrations and dietary protein consumption in essential tremor. Neurology. 2005 Aug 9;65(3):391-6.

Yetimalar Y, Irtman G, Gurgor N, Basoglu M. Olanzapine efficacy in the treatment of essential tremor. Eur J Neurol 2003 Jan;10(1): 79-82.

Zesiewicz TA, Ward CL, Hauser RA, Pease Campbell JA, Sullivan KL. Pregabalin (Lyrica) in the treatment of essential tremor. Mov Disord 2007 Jan;22(1):139-41.

Zesiewicz TA, Ward CL, Hauser RA, Salemi JL, Siraj S, Wilson MC, Sullivan KL. A pilot, double-blind, placebo-controlled trial of pregabalin (Lyrica) in the treatment of essential tremor. Mov Disord 2007 Jun 19.

Lyons K, Pahwa R, Comella CL, Eisa MS, Elble RJ, Fahn S, Jankovic J, Juncos JL, Koller WC, Ondo WG, Sethi KD, Stern MB, Tanner CM, Tintner R, Watts RL. Benefits and risks of pharmacological treatments for essential tremor. Drug Saf 2003; 26(7): 461-81.

Ondo WG, Jankovic J, Connor GS, Pahwa R, Elble R, Stacy MA, Koller WC, Schwarzman L, Wu SC, Hulihan JF; Topiramate Essential Tremor Study Investigators. Topiramate in essential tremor: a double-blind, placebo-controlled trial. Neurology 2006 Mar 14;66(5):672-7.

Connor GS, Edwards K, Tarsy D. Topiramate in essential tremor: findings from double-blind, placebo-controlled, crossover trials. Clin Neuropharmacol. 2008 Mar-Apr;31(2):97-103.

Bilodeau M, Keen DA, Sweeney PJ, Shields RW, Enoka RM. Strength training can improve steadiness in persons with essential tremor. Muscle Nerve. 2000 May;23(5):771-8.

Thursday, January 31, 2008

Epileptic medications and suicidal risk

This just in from the FDA....

...in placebo-controlled trials of 11 different medications used to treat epilepsy (and other disorders as detailed in previous posts), individuals using these medications experienced twice the risk of suicidal thoughts and/or behaviors. It didn't take long for some, only a week, to experience this very significant side effect. The risk WAS higher for those given these medications for epilepsy than those given the medications for other reasons.

This is the FDA's list of medications evaluated in this study:

Carbamazepine (Carbatrol, Equetro, Tegretol, Tegretol XR)
Felbamate (Felbatol)
Gabapentin (Neurontin)
Lamotrigine (Lamictal)
Levetiracetam (Keppra)
Oxcarbazepine (Trileptal)
Pregabalin (Lyrica)
Tiagabine (Gabitril)
Topiramate (Topamax)
Valproate (Depakote, Depakote ER, Depakene, Depacon)
Zonisamide ()

Here is the FDA reference for more information:

http://www.fda.gov/medwatch/safety/2008/safety08.htm#Antiepileptic


MY SOURCE: http://www.docguide.com/news/content.nsf/news/852571020057CCF6852573E1007057A9

Just a note from a nutritionist...fish oil can help reduce seizure activity. I AM NOT, I repeat AM NOT, advising anyone reading this post to discontinue their medications and replace them with a nutritional supplement. However, I AM encouraging you to discuss the possibility of a blend of nutrition therapy AND medication for a potentially gentler approach to safely managing a very serious medical issue.

Monday, January 14, 2008

Is Fibromyalgia A Real Disease? Does It Need Its Own Medication?

If you are interested in this debate, you may be interested in this New York Times article that was published today:

http://www.nytimes.com/2008/01/14/health/14pain.html?th&emc=th

Lyrica (pregabalin), the medication that is mentioned in this article, is a medication I've been researching for my psychotropic medication publication. This drug was first approved for use in the US in 2005, for the treatment of epilepsy, diabetic neuropathy pain and post-herpetic neuralgia. In 2007 it was also approved for treating fibromyalgia.

In addition, in my own research, I found publications describing 10 off-label (non-FDA approved)uses for this medication. One of these off-label uses, anxiety disorder, is actually an approved use in the European Union but not the United States. The references for these off-label uses, excerpted from my CD, are posted below.

Pregabalin is supposedly a more potent form of another popular medication, gabapentin (Neurontin). The use of this medication has been questioned, as at one point, it was estimated that 90% of its prescriptions were written for off-label uses. From what I could see when I was researching pregabalin, the trend with the newer version is not dissimilar.

From a biochemical standpoint, many of the off-label uses do make sense, as many of these issues have very similar biochemical origins. Off-label uses are not always inappropriate. However, it is important to make sure you know exactly WHY you are being prescribed a medication. You are entitled to ask your physician whether or not the medication you are being prescribed is FDA approved for your diagnosis, or if the use she is asking you to try is off-label. It's your body, and you have a right to make the most informed decision possible.

REFERENCES

http://en.wikipedia.org/wiki/Pregabalin
http://en.wikipedia.org/wiki/Gabapentin

Jatzko A, Stegmeier Petroianu A, Petroianu GA. Alpha-2-delta ligands for singultus (hiccup) treatment: three case reports. J Pain Symptom Manage 2007 Jun;33(6):756-60.
Yokoyama T, Maeda Y, Audette KM, Sluka KA.Pregabalin reduces muscle and cutaneous hyperalgesia in two models of chronic muscle pain in rats. J Pain 007 May;8(5):422-9.

Zesiewicz TA, Ward CL, Hauser RA, Pease Campbell JA, Sullivan KL. Pregabalin (Lyrica) in the treatment of essential tremor. Mov Disord 2007 Jan;22(1):139-41.
Zesiewicz TA, Ward CL, Hauser RA, Salemi JL, Siraj S, Wilson MC, Sullivan KL. A pilot, double-blind, placebo-controlled trial of pregabalin (Lyrica) in the treatment of essential tremor. Mov Disord 2007 Jun 19.

Maizels M, McCarberg B. Antidepressants and antiepileptic drugs for chronic non-cancer pain. Am Fam Physician 2005 Feb 1;71(3):483-90.

Crofford LJ, Rowbotham MC, Mease PJ, Russell IJ, Dworkin RH, Corbin AE, Young JP, LaMoreaux LK, Martin SA, Sharma U,Pregabalin 1008-105 Study Group. Pregabalin for the treatment of fibromyalgia syndrome: results of a randomized, double-blind, placebo-controlled trial. Arthritis Rheum 2005 Apr;52(4):1264-73.
Rooks DS. Fibromyalgia treatment update. Curr Opin Rheumatol 2007 Mar;19(2):111-7.

Owen RT. Pregabalin: Its efficacy, safety and tolerability profile in fibromyalgia syndrome. Drugs Today (Barc). 2007 Dec;43(12):857-63.

Pande AC, Crockatt JG, Feltner DE, Janney CA, Smith WT, Weisler R, Londborg PD, Bielski RJ, Zimbroff DL, Davidson JR, Liu Dumaw M. Pregabalin in generalized anxiety disorder: a placebo-controlled trial. Am J Psychiatry 2003 Mar;160(3):533-40.

Van Ameringen M, Mancini C, Pipe B, Bennett M. Antiepileptic drugs in the treatment of anxiety disorders: role in therapy. Drugs 2004;64(19):2199-220.

Baldwin DS, Polkinghorn C. Evidence-based pharmacotherapy of Generalized Anxiety Disorder. Int J Neuropsychopharmacol 2005 Jun;8(2):293-302.

Pohl RB, Feltner DE, Fieve RR, Pande AC. Efficacy of pregabalin in the treatment of generalized anxiety disorder: double-blind, placebo-controlled comparison of BID versus TID dosing. J Clin Psychopharmacol 2005 Apr;25(2):151-8.

Rickels K, Pollack MH, Feltner DE, Lydiard RB, Zimbroff DL, Bielski RJ, Tobias K, Brock JD, Zornberg GL, Pande AC. Pregabalin for treatment of generalized anxiety disorder: a 4-week, multicenter, double-blind, placebo-controlled trial of pregabalin and alprazolam. Arch Gen Psychiatry 2005 Sep;62(9):1022-30.

Keck PE, Strawn JR, McElroy SL. Pharmacologic treatment considerations in co-occurring bipolar and anxiety disorders. J Clin Psychiatry 2006;67 Suppl 1:8-15.

Montgomery SA, Tobias K, Zornberg GL, Kasper S, Pande AC. Efficacy and safety of pregabalin in the treatment of generalized anxiety disorder: a 6-week, multicenter, randomized, double-blind, placebo-controlled comparison of pregabalin and venlafaxine. J Clin Psychiatry 2006 May;67(5):771-82.

Frampton JE, Foster RH. Pregabalin: in the treatment of generalised anxiety disorder. CNS Drugs 2006;20(8):685-93.

Montgomery SA. Pregabalin for the treatment of generalised anxiety disorder. Expert Opin Pharmacother 2006 Oct;7(15):2139-54.

Bendelow B, Wedekind D, Leon T. Pregabalin for the treatment of generalized anxiety disorder: a novel pharmacologic intervention. Expert Rev Neurother 2007 Jul;7(7):769-81.

Owen RT. Pregabalin: its efficacy, safety and tolerability profile in generalized anxiety. Drugs Today (Barc). 2007 Sep;43(9):601-10.

Kitchener JM. Glossopharyngeal neuralgia responding to pregabalin. Headache 2006 Sep;46(8):1307-8.

Hurley RW, Chatterjea D, Rose Feng M, Taylor CP, Hammond DL. Gabapentin and pregabalin can interact synergistically with naproxen to produce antihyperalgesia. Anesthesiology 2002 Nov;97(5):1263-73.

Field MJ, Holloman EF, McCleary S, Hughes J, Singh L. Evaluation of gabapentin and S-(+)-3-isobutylgaba in a rat model of postoperative pain. J Pharmacol Exp Ther 1997 Sep;282(3):1242-6.

Jones DL, Sorkin LS. Systemic gabapentin and S(+)-3-isobutyl-gamma-aminobutyric acid block secondary hyperalgesia. Brain Res 1998 Nov 9;810(1-2):93-9.

Hill CM, Balkenohl M, Thomas DW, Walker R, Mathe H, Murray G. Pregabalin in patients with postoperative dental pain. Eur J Pain 2001;5(2):119-24.

Sommer M, Bachmann CG, Liebetanz KM, Schindehutte J, Tings T, Paulus W. Pregabalin in restless legs syndrome with and without neuropathic pain. Acta Neurol Scand 2007 May;115(5):347-50.

Jefferson JW. Benzodiazepines and anticonvulsants for social phobia (social anxiety disorder). J Clin Psychiatry 2001;62 Suppl 1:50-3.

Pande AC, Feltner DE, Jefferson JW, Davidson JR, Pollack M, Stein MB, Lydiard RB, Futterer R, Robinson P, Slomkowski M, DuBoff E, Phelps M, Janney CA, Werth JL. Efficacy of the novel anxiolytic pregabalin in social anxiety disorder: a placebo-controlled, multicenter study. J Clin Psychopharmacol 2004 Apr;23(2):141-9.

Muller JE, Koen L, Seedat S, Stein DJ. Social anxiety disorder : current treatment recommendations. CNS Drugs 2005;19(5):377-91.

Cottraux J. Recent developments in research and treatment for social phobia (social anxiety disorder). Curr Opin Psychiatry 2005 Jan;18(1):51-4.

Davidson JR. Pharmacotherapy of social anxiety disorder: what does the evidence tell us? J Clin Psychiatry 2006;67 Suppl 12:20-6.

Davidson JR. Pharmacotherapy of social phobia. Acta Psychiatr Scand Suppl 2003;(417):65-71.